Related references
Note: Only part of the references are listed.Early differential responses elicited by BRAFV600E in adult mouse models
Giuseppe Bosso et al.
CELL DEATH & DISEASE (2022)
FCX-146, a potent allosteric inhibitor of Akt kinase in cancer cells: Lead optimization of the second-generation arylidene indanone scaffold
Meenakshisundaram Balasubramaniam et al.
BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY (2021)
High-throughput virtual screening and preclinical analysis identifies CB-1, a novel potent dual B-Raf/c-Raf inhibitor, effective against wild and mutant variants of B-Raf expression in colorectal carcinoma
Mesfer Al Shahrani et al.
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2021)
Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
Beike Wang et al.
ONCOGENE (2021)
Novel HSP90-PI3K Dual Inhibitor Suppresses Melanoma Cell Proliferation by Interfering with HSP90-EGFR Interaction and Downstream Signaling Pathways
Qian Zhao et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Isorhamnetin Induces Melanoma Cell Apoptosis via the PI3K/Akt and NF-κB Pathways
Ran Duan et al.
BIOMED RESEARCH INTERNATIONAL (2020)
Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations
Dominika Rittler et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Anti-Cancer Activity of Ethanolic Leaf Extract of Salvia officinalis against Oral Squamous Carcinoma Cells in vitro via Caspase Mediated Mitochondrial Apoptosis
Prasanna Rajagopalan et al.
PHARMACOGNOSY MAGAZINE (2020)
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Jing Yang et al.
MOLECULAR CANCER (2019)
Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma
Mal Irvine et al.
ONCOGENESIS (2018)
A Multicenter Phase I Study Evaluating Dual PI3K andBRAFInhibition with PX-866and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors
Clinton Yam et al.
CLINICAL CANCER RESEARCH (2018)
4-Nerolidylcatechol: apoptosis by mitochondrial mechanisms with reduction in cyclin D1 at G0/G1 stage of the chronic myelogenous K562 cell line
Polyana Lopes Benfica et al.
PHARMACEUTICAL BIOLOGY (2017)
Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
Paola Queirolo et al.
Oncotarget (2016)
Resistant mechanisms to BRAF inhibitors in melanoma
Jose Luis Manzano et al.
ANNALS OF TRANSLATIONAL MEDICINE (2016)
Systematic analysis of BRAFV600E melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis
Mohammad Fallahi-Sichani et al.
MOLECULAR SYSTEMS BIOLOGY (2015)
Inhibitors of pan-PI3K signaling synergize with BRAF or MEK inhibitors to prevent BRAF-mutant melanoma cell growth
Melanie Sweetlove et al.
FRONTIERS IN ONCOLOGY (2015)
PI3′-Kinase Inhibition Forestalls the Onset of MEK1/2 Inhibitor Resistance in BRAF-Mutated Melanoma
Marian M. Deuker et al.
CANCER DISCOVERY (2015)
The clinical response to vemurafenib in a patient with a rare BRAFV600DK601del mutation-positive melanoma
Stephanie Trudel et al.
BMC CANCER (2014)
Searching in Mother Nature for Anti-Cancer Activity: Anti-Proliferative and Pro-Apoptotic Effect Elicited by Green Barley on Leukemia/Lymphoma Cells
Elisa Robles-Escajeda et al.
PLOS ONE (2013)
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
James A. McCubrey et al.
ONCOTARGET (2012)
Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma
Inna V. Fedorenko et al.
BIOCHEMICAL PHARMACOLOGY (2011)
Metformin inhibits melanoma development through autophagy and apoptosis mechanisms
T. Tomic et al.
CELL DEATH & DISEASE (2011)
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
William H. Chappell et al.
ONCOTARGET (2011)
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
Sarah E. M. Herman et al.
BLOOD (2010)
PTEN and the PI3-Kinase Pathway in Cancer
Nader Chalhoub et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2009)
Structural comparisons of class I phosphoinositide 3-kinases
L. Mario Amzel et al.
NATURE REVIEWS CANCER (2008)
Three distinct stages of apoptotic nuclear condensation revealed by time-lapse imaging, biochemical and electron microscopy analysis of cell-free apoptosis
Shigenobu Tone et al.
EXPERIMENTAL CELL RESEARCH (2007)
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
James A. McCubrey et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
Share Paper
